Stock Analysis
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Alnylam Pharmaceuticals, Inc. (ALNY) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Alnylam Pharmaceuticals, Inc. (ALNY) currently has an AIQ Score of 43/100, indicating a neutral setup. Quality is the strongest factor at 86/100. Momentum is the weakest current factor at 16/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ALNY at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $165.00 |
| AIQ Score | 43/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $32.93B |
| P/E Ratio (TTM) | 40.35 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $1.23 |
| Revenue (quarter ended 2026-06-30) | $1.29B |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.28 |
| Volume | 7.06M |
| 52-week range | $172.31-$482.73 |
| RSI 14 | 22.02 |
| 50-Day SMA | $237.78 |
| 200-Day SMA | $286.49 |
| Analyst Price Target | $361.10 |
| Next Earnings | Feb 11, 2027 |
ALNYAlnylam Pharmaceuticals, Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum16
- Value25
- Quality86
- Risk resilience41
- Sentiment—
ALNY Stock Analysis Summary
Alnylam Pharmaceuticals, Inc. (ALNY) currently has an AIQ Score of 43/100, indicating a neutral setup. Quality is the strongest factor at 86/100. Momentum is the weakest current factor at 16/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, ALNY has AIQ Score of 43/100 with Quality base of 86/100 and fading Momentum at 16/100. Wait for component alignment before adding exposure.
Quality (86/100) leads while Momentum (16/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -5.17% stock move · ALNY classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ALNY Bullish or Bearish Right Now?
ALNY currently has a neutral overall setup. Quality is the strongest factor at 86/100, while Momentum is weakest at 16/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 86/100.
- - Analyst target implies +118.85% upside from the latest quote.
- - Value is the current constraint at 25/100.
- - Momentum is weak at 16/100.
- - Risk Resilience is weak at 41/100.
- - Price is -39.26% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (38 vs 5).
Current Consensus
ALNY's Technical Analysis Consensus is currently Strong Sell, with 5 buy, 2 neutral, and 38 sell votes. ALNY's 14-day RSI is 22.02, which places the stock in an oversold momentum range. ALNY's beta is 0.28, indicating lower market sensitivity than the broad market.
What Changed in ALNY?
The largest recent change in ALNY is Momentum moving down by 34.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the ALNY Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ALNY Decision Framework
Public evidence layers, setup checks, and risk context for Alnylam Pharmaceuticals, Inc..
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Alnylam Pharmaceuticals, Inc. has an AIQ Score of 43/100 in a Neutral regime. Quality is strongest at 86/100. Beta is 0.27, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ALNY is in a Neutral AIQ regime with score 43/100. |
| Signal Conflict | The primary conflict is that quality leads at 86/100 while momentum lags at 16/100. |
| Factor Evidence | Momentum 16/100 · Value 25/100 · Quality 86/100 · Risk 41/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 86/100.
Momentum is 16/100 and RSI (14) is 22.0.
ALNY is in a Neutral regime at 43/100.
Risk factor is 41/100 with beta 0.27 and annual volatility 54.27%.
Current conflict: quality leads at 86/100 while momentum lags at 16/100.
ALNY Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ALNY Fundamentals
ALNY valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ALNY Technical Analysis
ALNY technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ALNY Stock Catalysts
Track ALNY earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ALNY Dividend Analysis
ALNY dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ALNY Financial Data
ALNY revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ALNY Risk Analysis
ALNY volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ALNY Stock News
ALNY stock news, market tone, recent headlines, and catalyst context.
ALNY vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: ALNY · ARWR · BDTX · BEAM · CRSP. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ALNY Current stock | 43/100 | 25/100 | 16/100 | 41/100 | -1.65 | 54.27% | Current |
| ARWR Arrowhead Pharmaceuticals | 38/100 | 34/100 | 38/100 | 55/100 | 0.9 | 61.76% | ALNY vs ARWR |
| BDTX Black Diamond Therapeutics | 35/100 | — | 43/100 | 37/100 | -0.49 | 81.98% | ALNY vs BDTX |
| BEAM Beam Therapeutics | 45/100 | 34/100 | 74/100 | 36/100 | 0.51 | 71.71% | ALNY vs BEAM |
| CRSP CRISPR Therapeutics | 36/100 | 34/100 | 52/100 | 40/100 | -0.03 | 57.59% | ALNY vs CRSP |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ALNY
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ALNY
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ALNY Stock FAQ
What is ALNY stock price today?
Alnylam Pharmaceuticals, Inc.'s current stock price is $165.00. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ALNY bullish or bearish right now?
ALNY's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ALNY's market cap?
ALNY's market cap is $32.93B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ALNY's current P/E ratio?
ALNY's current P/E ratio is 40.35 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ALNY's RSI?
ALNY's 14-day RSI is 22.02 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ALNY above its 50-day and 200-day moving averages?
ALNY is -26.82% from its 50-day SMA and -39.26% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ALNY's next earnings date?
ALNY's next earnings date is currently listed as Feb 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ALNY pay a dividend?
ALNY's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.